Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akouos, Inc.AKUS · Entity 11574 | Director | June 23, 2022 | June 27, 2022 |
| NEOGENOMICS INCNEO · Entity 2096 | Chief Executive Officer | February 23, 2025 | February 25, 2025 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
| QuidelOrtho CorpQDEL · Entity 4986 | Director | June 06, 2023 | June 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akouos, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2032-06-22 | Direct | 16,000 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 16,000 · Balance 16,000 F1: This option was granted on June 23, 2022. The shares underlying the option will fully vest on the earlier of (i) June 23, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 23, 2022. The shares underlying the option will fully vest on the earlier of (i) June 23, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders.
NEOGENOMICS INC
Report date February 23, 2025 · Filed February 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 641,585 |
Ending reported balance
After 2025-02-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-23 · Exercise / conversion · Acquired 57,413 · Balance 655,652 F1: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Row 2 · 2025-02-23 · Tax withholding · Disposed 14,067 · Balance 641,585 F2: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 114,826 |
Reported balance
After 2025-02-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-23 · Exercise / conversion · Disposed 57,413 · Balance 114,826 F3: On February 23, 2024, Mr. Smith was granted 172,239 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 96,127 |
Reported balance
Holding disclosure · report date 2025-02-23 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 96,127 F7: On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2029-08-15 | Direct | 694,444 |
Reported balance
Holding disclosure · report date 2025-02-23 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 694,444 F5: On August 15, 2022, Mr. Smith was granted 694,444 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.65 · Expires 2030-05-11 | Direct | 269,841 |
Reported balance
Holding disclosure · report date 2025-02-23 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 269,841 F6: On May 11, 2023, Mr. Smith was granted 269,841 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 144,190 |
Reported balance
Holding disclosure · report date 2025-02-23 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 144,190 F8: On May 11, 2023, Mr. Smith was granted 144,190 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 216,285. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F4: Once vested, the shares of common stock are not subject to expiration. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 172,240 |
Reported balance
Holding disclosure · report date 2025-02-23 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 172,240 F10: On February 23, 2024, Mr. Smith was granted 172,240 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 258,360. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F4: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2034-02-23 | Direct | 287,940 |
Reported balance
Holding disclosure · report date 2025-02-23 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 287,940 F9: On February 23, 2024, Mr. Smith was granted 287,940 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
F2: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
F3: On February 23, 2024, Mr. Smith was granted 172,239 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F4: Once vested, the shares of common stock are not subject to expiration.
F5: On August 15, 2022, Mr. Smith was granted 694,444 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F6: On May 11, 2023, Mr. Smith was granted 269,841 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F7: On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F8: On May 11, 2023, Mr. Smith was granted 144,190 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 216,285. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
F9: On February 23, 2024, Mr. Smith was granted 287,940 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F10: On February 23, 2024, Mr. Smith was granted 172,240 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 258,360. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 223,492 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 223,492 · Balance 223,492 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
QuidelOrtho Corp
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,249 |
Reported balance
After 2023-06-06 transaction · row 1
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 2,248 · Balance 2,249 F1: Reflects release of restricted stock units that were previously reported on a Form 4. |
| Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-06-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-06 · Exercise / conversion · Disposed 2,248 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3: The restricted stock units vested on June 6, 2023. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 33,328 |
Reported balance
Holding disclosure · report date 2023-06-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 33,328 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on a Form 4.
F2: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F3: The restricted stock units vested on June 6, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ortho Clinical Diagnostics Holdings plc
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, $0.00001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 367,360 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated December 22, 2021 (the "BCA"), by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time, each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.56 · Expires 2029-12-20 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 1,971,420 · Balance 0 F2: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated December 22, 2021 (the "BCA"), by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time, each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash.
F2: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 21:25 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 223,492 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001299130-26-000104 · wk-form4_1780608317.xml · derivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,492 Underlying: Common Stock · 223,492 shares Expires 2036-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:06 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001299130-25-000131 · wk-form4_1749240357.xml · derivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:37 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 57,413 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000039 · wk-form4_1740519447.xml · derivative · entry 3 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,826 Underlying: Common Stock · 57,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 23, 2024, Mr. Smith was granted 172,239 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:37 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 14,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000039 · wk-form4_1740519447.xml · nonDerivative · entry 2 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 641,585 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:37 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 57,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000039 · wk-form4_1740519447.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 00:22 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 72,901 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001299130-25-000022 · wk-form4_1738628535.xml · derivative · entry 2 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,901 Underlying: Common Stock · 72,901 shares Expires 2035-01-30 F2 · derivative.exercise_date: One-third of the shares subject to the option will vest on January 30, 2026, which is the one year anniversary of Mr. Smith joining the Board, and the remainder will vest in equal monthly installments thereafter for 24 months on the same date of the month as his initial start date, provided he continues to serve as a director through each vesting date. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 00:22 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 54,099 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-25-000022 · wk-form4_1738628535.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,099 F1 · shares: Mr. Smith was elected to the Board of Directors on January 30, 2025. Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on January 30th of each of 2026, 2027, and 2028, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 33,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000143 · wk-form4_1724098745.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 646,302 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the August 15, 2024 vesting of restricted stock. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 48,063 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000075 · wk-form4_1715737144.xml · derivative · entry 4 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,127 Underlying: Common Stock · 48,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 48,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000075 · wk-form4_1715737144.xml · nonDerivative · entry 3 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 679,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 18,913 | $14.86 | $281,047.18 |
DisclosureSEC source: 0001077183-24-000075 · wk-form4_1715737144.xml · nonDerivative · entry 2 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 631,369 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 48,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000075 · wk-form4_1715737144.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| May 11, 2024 Filed Dec 4, 2024 21:09 UTC Amendment | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 48,063 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000168 · wk-form4a_1733346539.xml · derivative · entry 3 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,127 Underlying: Common Stock · 48,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three year anniversary dates of the grant date. F5 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2024 Filed Dec 4, 2024 21:09 UTC Amendment | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 18,913 | $14.86 | $281,047.18 |
DisclosureSEC source: 0001077183-24-000168 · wk-form4a_1733346539.xml · nonDerivative · entry 2 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 631,369 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. F3 · balance_after: On May 14, 2024, the reporting person filed a Form 4 which inadvertently reported the number of shares of common stock received upon the vesting of certain of his RSUs twice. In fact, as reported in this amendment, the reporting person directly owned 631,369 shares of common stock after the vesting of 48,063 RSUs and reported withholding. The error effected the number of shares reported in Column 5 of Table I of each of the reporting person's subsequent filings on Form 4. Read SEC document |
| May 11, 2024 Filed Dec 4, 2024 21:09 UTC Amendment | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 48,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000168 · wk-form4a_1733346539.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:28 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantPerformance Stock Unit · Derivative | 172,240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000028 · wk-form4_1709069286.xml · derivative · entry 8 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,240 Underlying: Common Stock · 172,240 shares Expires not disclosed F8 · derivative.exercise_date: On February 23, 2024, Mr. Smith was granted 172,240 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 258,360. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:28 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 172,239 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000028 · wk-form4_1709069286.xml · derivative · entry 7 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,239 Underlying: Common Stock · 172,239 shares Expires not disclosed F7 · derivative.exercise_date: On February 23, 2024, Mr. Smith was granted 172,239 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:28 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 287,940 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001077183-24-000028 · wk-form4_1709069286.xml · derivative · entry 6 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,940 Underlying: Common Stock · 287,940 shares Expires 2034-02-23 F6 · derivative.exercise_date: On February 23, 2024, Mr. Smith was granted 287,940 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:29 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035401 · doc4.xml · derivative · entry 3 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on June 6, 2023. F3 · derivative.expiration_date: The restricted stock units vested on June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:29 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035401 · doc4.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,249 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 27, 2023 Filed May 31, 2023 20:05 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Tax withholdingCommon Stock | 1,225 | $85.54 | $104,786.50 |
DisclosureSEC source: 0001209191-23-033101 · doc4.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,329 F1 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the vesting of previously granted restricted stock awards. Read SEC document |
| May 24, 2023 Filed May 26, 2023 00:21 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Premium) · Derivative | 80 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032333 · doc4.xml · derivative · entry 3 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80 Underlying: Common Stock · 80 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 24, 2024. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on May 24, 2024. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| May 24, 2023 Filed May 26, 2023 00:21 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Converted) · Derivative | 402 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032333 · doc4.xml · derivative · entry 2 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402 Underlying: Common Stock · 402 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 24, 2023. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 24, 2023. Read SEC document |
| May 24, 2023 Filed May 26, 2023 00:21 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Equity Grant) · Derivative | 2,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032333 · doc4.xml · derivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,416 Underlying: Common Stock · 2,416 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 24, 2024. F2 · derivative.expiration_date: The restricted stock units vest on May 24, 2024. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantPerformance Stock Unit · Derivative | 144,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000054 · wf-form4_168418480755854.xml · derivative · entry 5 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,190 Underlying: Common Stock · 144,190 shares Expires not disclosed F5 · derivative.exercise_date: On May 11, 2023, Mr. Smith was granted 144,190 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 216,285. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 144,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000054 · wf-form4_168418480755854.xml · derivative · entry 4 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,190 Underlying: Common Stock · 144,190 shares Expires not disclosed F3 · derivative.exercise_date: On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 269,841 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001077183-23-000054 · wf-form4_168418480755854.xml · derivative · entry 3 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,841 Underlying: Common Stock · 269,841 shares Expires 2030-05-11 F2 · derivative.exercise_date: On May 11, 2023, Mr. Smith was granted 269,841 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:13 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 694,444 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001077183-22-000148 · wf-form4_166077800532643.xml · derivative · entry 3 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694,444 Underlying: Common Stock · 694,444 shares Expires 2029-08-15 F3 · derivative.exercise_date: On August 15, 2022, Mr. Smith was granted 694,444 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:13 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 265,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000148 · wf-form4_166077800532643.xml · nonDerivative · entry 2 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,219 F2 · shares: On August 15, 2022, Mr. Smith was granted 265,452 restricted stock awards. These awards vest on the fourth anniversary date of the grant date. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:13 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 336,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000148 · wf-form4_166077800532643.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,767 F1 · shares: On August 15, 2022, Mr. Smith was granted 336,767 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 17:05 UTC | Akouos, Inc. AKUS · Entity 11574 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-22-074831 · tm2219359-5_4seq1.xml · derivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: This option was granted on June 23, 2022. The shares underlying the option will fully vest on the earlier of (i) June 23, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:20 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Equity Grant) · Derivative | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035179 · doc4.xml · derivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,248 Underlying: Common Stock · 2,248 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on June 6, 2023. F2 · derivative.expiration_date: The restricted stock units vest on June 6, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:30 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantStock Options · Derivative | 207,984 | $0.00 Strike: $119.06 | $0.00 |
DisclosureSEC source: 0000899243-22-020478 · doc4.xml · derivative · entry 2 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,984 Underlying: Common Stock · 207,984 shares Expires 2029-12-20 F3 · kind: Pursuant to the Business Combination Agreement, each Ortho stock option was converted into an equal number of Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions), except as adjusted by the Business Combination Agreement. F4 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:30 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 34,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020478 · doc4.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,554 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation, Ortho Clinical Diagnostics Holdings plc ("Ortho"), QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each ordinary share of Ortho beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for (i) 0.1055 shares of common stock of QuidelOrtho and (ii) $7.14 in cash. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation, Ortho Clinical Diagnostics Holdings plc ("Ortho"), QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each ordinary share of Ortho beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for (i) 0.1055 shares of common stock of QuidelOrtho and (ii) $7.14 in cash. F2 · balance_after: Includes 29,418 restricted stock awards, of which 2,101 shares will vest on July 28, 2022, 8,404 shares will vest on September 9, 2022, 2,100 shares will vest on February 28, 2023 and 8,406 shares will vest on May 27, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 20:15 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | Disposition to issuerStock Option · Derivative | 1,971,420 | Not disclosed Strike: $12.56 | Not disclosed |
DisclosureSEC source: 0000899243-22-020381 · doc4.xml · derivative · entry 2 Smith Christopher M · CIK 0001436707 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, $0.00001 par value · 1,971,420 shares Expires 2029-12-20 F2 · price: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. F2 · derivative.exercise_date: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 20:15 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | Disposition to issuerOrdinary Shares, $0.00001 par value | 367,360 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020381 · doc4.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Business Combination Agreement, dated December 22, 2021 (the "BCA"), by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time, each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash. Read SEC document |
| May 27, 2022 Filed Aug 1, 2022 23:17 UTC Amendment | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 34,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-043762 · doc4a.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,554 F1 · date: The Form 4 originally filed on June 1, 2022 is being amended to correct the vesting schedule with respect to 29,418 restricted stock awards held by the reporting person. F2 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation, Ortho Clinical Diagnostics Holdings plc ("Ortho"), QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc., and Orca Holdco 2, Inc., each ordinary share of Ortho beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for (i) 0.1055 shares of common stock of QuidelOrtho and (ii) $7.14 in cash. F2 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation, Ortho Clinical Diagnostics Holdings plc ("Ortho"), QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc., and Orca Holdco 2, Inc., each ordinary share of Ortho beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for (i) 0.1055 shares of common stock of QuidelOrtho and (ii) $7.14 in cash. F3 · balance_after: Includes 29,418 restricted stock awards, of which 4,203 shares vested on July 28, 2022, 16,811 shares will vest on September 9, 2022, 4,201 shares will vest on February 28, 2023 and 4,203 shares will vest on May 27, 2023. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:23 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | Exercise / conversionStock Option · Derivative | 100,000 | $0.00 Strike: $12.56 | $0.00 |
DisclosureSEC source: 0001209191-22-001678 · doc4.xml · derivative · entry 3 Smith Christopher M · CIK 0001436707 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,710 Underlying: Ordinary Shares, $0.00001 par value · 100,000 shares Expires 2029-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in three equal annual installments beginning on September 9, 2020. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:23 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | SaleOrdinary Shares, $0.00001 par value | 100,000 | $21.10 | $2,109,800.00 |
DisclosureSEC source: 0001209191-22-001678 · doc4.xml · nonDerivative · entry 2 Smith Christopher M · CIK 0001436707 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,360 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The Reporting Person undertakes to provide, upon request by the Securities Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported in this Form 4. F3 · price: Represents the weighted average sales price for the price increments ranging from $21.0000 to $21.4000 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:23 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | Exercise / conversionOrdinary Shares, $0.00001 par value | 100,000 | $12.56 | $1,256,000.00 |
DisclosureSEC source: 0001209191-22-001678 · doc4.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2021 Filed Aug 4, 2021 22:29 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | SaleOrdinary Shares, $0.00001 par value | 61,800 | $21.79 | $1,346,622.00 |
DisclosureSEC source: 0001209191-21-049757 · doc4.xml · nonDerivative · entry 3 Smith Christopher M · CIK 0001436707 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,360 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The Reporting Person undertakes to provide, upon request by the Securities Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported in this Form 4. F5 · price: Represents the weighted average sales price for the price increments from $21.57 to $21.92. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 22:29 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | SaleOrdinary Shares, $0.00001 par value | 104,987 | $21.55 | $2,262,826.81 |
DisclosureSEC source: 0001209191-21-049757 · doc4.xml · nonDerivative · entry 2 Smith Christopher M · CIK 0001436707 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,160 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The Reporting Person undertakes to provide, upon request by the Securities Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported in this Form 4. F4 · price: Represents the weighted average sales price for the price increments from $21.00 to $21.90. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:29 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | SaleOrdinary Shares, $0.00001 par value | 103,213 | $22.10 | $2,281,038.26 |
DisclosureSEC source: 0001209191-21-049757 · doc4.xml · nonDerivative · entry 1 Smith Christopher M · CIK 0001436707 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,147 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The Reporting Person undertakes to provide, upon request by the Securities Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported in this Form 4. F3 · price: Represents the weighted average sales price for the price increments from $21.90 to $22.51. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 16:35 UTC | Akouos, Inc. AKUS · Entity 11574 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001104659-21-085756 · tm2120686-2_4seq1.xml · derivative · entry 1 Smith Christopher M · CIK 0001436707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-06-23 F1 · derivative.exercise_date: This option was granted on June 24, 2021. The shares underlying the option will fully vest on the earlier of (i) June 24, 2022 and (ii) the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.